Manipulating the Peri-Infarct Area Using Maraviroc to Enhance Motor Skills After Stroke

Recruiting now · Phase 2 · Has a placebo group

Conditions studied: Ischemic Stroke, Stroke, Stroke Acute

In brief

MASTER is a single-center, patient and investigator-blinded, Randomized Controlled Trial (RCT) to compare the efficacy of Maraviroc, a C-C chemokine receptor 5 (CCR5) antagonist, against placebo regarding motor function and motor learning skills in the first 3 months after ischemic stroke.

Key facts

Study ID
NCT07080567
Run by
Emmanuel Carrera
People needed
80
Starts
2025-07-14
Expected to finish
2027-12-01
Last updated by the study team
2025-08-12

Who can join

Age: 18 and older. Sex: any. Healthy volunteers: not accepted.

You may qualify if…

You may not qualify if…

Where it is running

Full record on ClinicalTrials.gov

Trial information comes from ClinicalTrials.gov and is refreshed daily. TrialsForMe does not provide medical care and does not run the studies it lists.